Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about "Intellectual Property Rights Pharma India "

Lupin's Aurangabad Facility Receives EIR from U.S. FDA

Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) from the U.S. FDA for its Aurangabad, India facility. The inspection for the facility was carried out by the U.S. FDA between February 10, 2020 and February 14, 2020 and concluded with no observations

Intellectual Property Rights Pharma India | 03/04/2020 | By Darshana | 1058

BELLUS Health Announces Closing of Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovations

BELLUS Health Inc.is pleased to announce that it has closed the transaction announced on March 23, 2020 in accordance with the asset purchase and sale agreement entered into with adMare BioInnovations’ NEOMED Institute

Intellectual Property Rights Pharma India | 27/03/2020 | By Darshana | 355

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members